Patent ID: 9481709
Filing Date: 2016-11-01
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of treating a mammal having obesity or excessive weight, or a mammal suffering from abnormal fat metabolism disease selected from type II diabetes and hypertriglyceridemia, comprising the step of administering to said mammal at least one compound which inhibits the enzymatic activity of an enteropeptidase, wherein the compound is selected from the group consisting of: Glu-Gly-BoroArg, Ala-Phe-BoroArg, Glu-Gly-BoroLys, Ala-Phe-BoroLys, Ac-Glu-Gly-BoroArg, Ac-Ala-Phe-BoroArg, Ac-Glu-Gly-BoroLys, and Ac-Ala-Phe-BoroLys, wherein Ac is acetyl, Glu is glutamic acid, Gly is glycine, Ala is alanine, Phe is phenylalanine, BoroArg is boroarginine, and BoroLys is borolysine; the BoroArg or BoroLys moieties having a functional group of selected from the group consisting of: wherein the compound is non-absorbable, and selectively inhibits the enzymatic activity of an enteropeptidase localized in the intestine over other, systemically localized serine proteases.